Attovia Therapeutics, Inc.: 5%+ holders

As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Attovia Therapeutics, Inc. The largest reported stake is Frazier Life Sciences Public Fund, L.P.'s, at 13.5%. 2 filings are on record since August 11, 2026 (Schedule 13D, August 11, 2026).

Frazier Life Sciences Public Fund, L.P. also filed stake reports on 25 other companies ↓

Sell to companies like Attovia Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Attovia Therapeutics, Inc. has 2 Schedule 13D or 13G filings on record since 2026-08-11. 2 holders' latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Attovia Therapeutics, Inc. and the warning signs.

See Attovia Therapeutics, Inc.'s free Snapshot Watch Attovia Therapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Attovia Therapeutics, Inc. and the records around it.

Attovia Therapeutics, Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• Frazier Life Sciences Public Fund, L.P. also filed stake reports on 25 other companies: PHATHOM PHARMACEUTICALS, INC. (Nov 2026), Q32 Bio Inc. (Oct 2026), ACLARIS THERAPEUTICS, INC. (Sep 2026)
• Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)

Want the whole picture on Attovia Therapeutics, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Attovia Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Attovia Therapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   6 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Attovia Therapeutics, Inc. by CUSIP 04987L102 and gives its principal executive office as 1091 Industrial Road, Suite 310, San Carlos, CA 94070 (SCHEDULE 13G, 2026-08-12).

Source of funds (Item 3)

Prior to the Issuer's initial public offering (the "IPO"), FLS XI purchased from the Issuer in a series of private transactions, (i) 75,350 shares of Common Stock (after accounting for the 9.29-1 reverse stock split effected on July 29, 2026), (ii) 16,250,000 shares of Series A-1 Preferred Stock, (iii) 14,772,727 shares of Series A-2 Preferred Stock, (iv) 11,054,544 shares of Series B Preferred Stock and (v) 8,930,685 shares of Series C Preferred Stock, for an aggregate total purchase price of approximately $59,979,760.Frazier Life Sciences Public Fund, L.P., SCHEDULE 13D, 2026-08-11

Purpose of Transaction (Item 4)

Frazier Life Sciences Public Fund, L.P.

The Reporting Persons acquired the Common Stock reported herein for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, the Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation …The first part of Item 4 of the SCHEDULE 13D filed 2026-08-11; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Attovia Therapeutics, Inc.

Who owns Attovia Therapeutics, Inc.?

On this page, 2 holders' latest ownership filings report 5% or more of Attovia Therapeutics, Inc.: Frazier Life Sciences Public Fund, L.P. (13.5%, Schedule 13D, filed 2026-08-11) and Deep Track Capital, LP (7.45%, Schedule 13G, filed 2026-08-12).

Who are the largest shareholders of Attovia Therapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of Attovia Therapeutics, Inc. on this page are Frazier Life Sciences Public Fund, L.P. (13.5%) and Deep Track Capital, LP (7.45%).

When did Frazier Life Sciences Public Fund, L.P. buy into Attovia Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Frazier Life Sciences Public Fund, L.P. on this page is the Schedule 13D, filed 2026-08-11, reporting 13.5%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Attovia Therapeutics, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Attovia Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Attovia Therapeutics, Inc. is mentioned again
• Find former Attovia Therapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes